Klivira
Request demo

Navigating UnitedHealthcare Trodelvy Prior Authorization

Klivira automates the complex process of obtaining UnitedHealthcare Trodelvy prior authorization, ensuring efficient submissions for this high-volume specialty oncology medication.

For revenue cycle teams and prior authorization coordinators, managing specialty drug PAs can be a significant operational burden. Trodelvy (sacituzumab govitecan) often requires prior authorization across UnitedHealthcare's commercial, Medicare Advantage, and Medicaid managed care plans, necessitating precise adherence to payer-specific criteria and submission protocols to prevent delays and denials.

Understanding Trodelvy and UnitedHealthcare's Specialty Drug Program

Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate used in the treatment of certain metastatic cancers, including triple-negative breast cancer. As a high-cost specialty medication, it consistently requires prior authorization from UnitedHealthcare. Klivira helps navigate the specific pathways for specialty drugs, which often involve OptumRx for pharmacy benefits or direct medical benefit review, sometimes with site-of-care considerations.

UnitedHealthcare Prior Authorization Submission Channels

UnitedHealthcare directs medical benefit prior authorization submissions primarily through the UnitedHealthcare Provider Portal at uhcprovider.com. For pharmacy benefit PAs, OptumRx manages submissions, which can be initiated via their provider PA system or through ePA partners like CoverMyMeds and Surescripts. X12 278 transactions are also supported via clearinghouses for medical benefit procedures requiring prior authorization.

Medical Necessity Criteria for Trodelvy (Sacituzumab Govitecan)

UnitedHealthcare's medical necessity criteria for oncology drugs like Trodelvy are published in their Medical Policy Library. These policies often reference external standards, such as the NCCN Clinical Practice Guidelines in Oncology (NCCN Compendium), to establish coverage requirements based on specific indications, dosing, and patient characteristics. Adherence to these evidence-based guidelines is critical for a successful prior authorization.

Turnaround Times and Regulatory Considerations

Prior authorization turnaround times for UnitedHealthcare are governed by state-specific insurance regulations for commercial plans and by NCQA Utilization Management accreditation standards. For Medicare Advantage and UnitedHealthcare Community Plan (Medicaid managed care) lines, CMS-0057-F mandates 72-hour decisions for standard PAs and 24-hour decisions for expedited PAs, with phased compliance timelines. Klivira's automation helps track these critical timeframes.

Common Denial Reasons and Appeal Pathways for Trodelvy

Denials for Trodelvy prior authorizations often stem from insufficient clinical documentation, failure to meet medical necessity criteria (e.g., lack of NCCN compendium support for off-label use), or non-adherence to step therapy requirements. UnitedHealthcare provides distinct appeal pathways for commercial, Medicare Advantage, and Medicaid lines of business, including peer-to-peer reviews for clinical denials and expedited appeal options for urgent cases.

Frequently asked questions

How do I submit a prior authorization for Trodelvy to UnitedHealthcare?

Submissions for Trodelvy depend on whether it falls under the medical or pharmacy benefit. Medical benefit PAs are typically submitted via uhcprovider.com or X12 278. Pharmacy benefit PAs, managed by OptumRx, can be submitted through OptumRx's system or ePA partners like CoverMyMeds and Surescripts.

What clinical documentation does UnitedHealthcare require for Trodelvy PA?

UnitedHealthcare generally requires documentation demonstrating medical necessity as per their published medical policies, which often align with NCCN Compendium guidelines for oncology. This includes patient diagnosis, prior treatment history, current clinical status, and supporting lab or imaging results.

Who handles Trodelvy prior authorizations for UnitedHealthcare?

For UnitedHealthcare members, Trodelvy prior authorizations are typically handled by OptumRx if it falls under the pharmacy benefit, or through UnitedHealthcare's medical review process if under the medical benefit. The specific pathway depends on the member's plan and the therapeutic category.

What are common reasons for UnitedHealthcare to deny Trodelvy prior authorization?

Common denial reasons include insufficient clinical documentation to support medical necessity, lack of adherence to step therapy protocols, or off-label use without adequate NCCN compendium support. Site-of-service policies for infusions can also lead to denials if not followed.

How can Klivira help with UnitedHealthcare Trodelvy prior authorizations?

Klivira automates the prior authorization workflow by integrating with your EMR and connecting directly with UnitedHealthcare's submission channels, including uhcprovider.com and X12 278. This reduces manual effort, accelerates submission, and helps ensure all required documentation aligns with UHC's medical necessity criteria for Trodelvy.

Related coverage

Other trodelvy prior authorization by payer

Other trodelvy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo